Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials.

[1]  J. McMurray,et al.  Dapagliflozin in Patients with Chronic Kidney Disease. , 2020, The New England journal of medicine.

[2]  C. Cannon,et al.  Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. , 2020, The New England journal of medicine.

[3]  P. Ponikowski,et al.  Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. , 2020, The New England journal of medicine.

[4]  G. Filippatos,et al.  SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials , 2020, The Lancet.

[5]  Sandeep R. Das,et al.  2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee. , 2020, Journal of the American College of Cardiology.

[6]  Jeffrey M. Turner,et al.  Empagliflozin in Heart Failure , 2020, Circulation.

[7]  S. Bangalore,et al.  Risk of Amputation Associated with Sodium-Glucose Co-Transporter 2 Inhibitors: A Meta-Analysis of Five Randomized Controlled Trials. , 2020, Diabetes research and clinical practice.

[8]  Akshay S. Desai,et al.  Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. , 2020, JAMA.

[9]  M. Pfeffer,et al.  Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial , 2020, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[10]  Liming Chen,et al.  Effects of SGLT2 inhibitors on fractures and bone mineral density in type 2 diabetes: An updated meta‐analysis , 2019, Diabetes/metabolism research and reviews.

[11]  Akshay S. Desai,et al.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.

[12]  R. Gilbert,et al.  Acute kidney injury with sodium‐glucose co‐transporter‐2 inhibitors: A meta‐analysis of cardiovascular outcome trials , 2019, Diabetes, obesity & metabolism.

[13]  B. Zinman,et al.  Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups , 2019, Circulation.

[14]  S. Goto,et al.  Possible Mechanism of Hematocrit Elevation by Sodium Glucose Cotransporter 2 Inhibitors and Associated Beneficial Renal and Cardiovascular Effects. , 2019, Circulation.

[15]  B. Zinman,et al.  Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. , 2019, The New England journal of medicine.

[16]  Declare–Timi Investigators.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019 .

[17]  Marc P. Bonaca,et al.  SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials , 2019, The Lancet.

[18]  K. Mahaffey,et al.  Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function , 2018, Circulation.

[19]  S. Lippmann,et al.  Risks vs Benefits for SGLT2 Inhibitor Medications. , 2018, Federal practitioner : for the health care professionals of the VA, DoD, and PHS.

[20]  A. Durães,et al.  SGLT2 inhibition and heart failure—current concepts , 2018, Heart Failure Reviews.

[21]  S. Solomon,et al.  Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus , 2018, Circulation.

[22]  P. Reynier,et al.  SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials , 2018, Acta Diabetologica.

[23]  M. Khan,et al.  Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis , 2018, European journal of preventive cardiology.

[24]  B. Zinman,et al.  Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease , 2018, Circulation.

[25]  Biao Xu,et al.  Cardiovascular Safety, Long‐Term Noncardiovascular Safety, and Efficacy of Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta‐Analysis With Trial Sequential Analysis , 2018, Journal of the American Heart Association.

[26]  B. Zinman,et al.  How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial , 2017, Diabetes Care.

[27]  M. Monami,et al.  Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials. , 2017, Diabetes research and clinical practice.

[28]  K. Mahaffey,et al.  Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes , 2017, The New England journal of medicine.

[29]  H. Heerspink,et al.  Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment. , 2017, Journal of the American Society of Nephrology : JASN.

[30]  E. Ferrannini,et al.  CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis , 2016, Diabetes Care.

[31]  B. Zinman,et al.  Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial , 2016, European heart journal.

[32]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[33]  U. Broedl,et al.  Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus , 2014, Circulation.

[34]  D. de Zeeuw,et al.  Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes , 2013, Diabetes, obesity & metabolism.

[35]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.